Swiss National Bank Revance Therapeutics, Inc. Transaction History

Swiss National Bank

  • $150 Billion
  • Q3 2024

A detailed history of Swiss National Bank transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 194,650 shares of RVNC stock, worth $500,250. This represents 0.0% of its overall portfolio holdings.

Number of Shares
194,650
Previous 194,650 -0.0%
Holding current value
$500,250
Previous $500,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024
BUY
$4.65 - $9.31 $139,500 - $279,300
30,000 Added 18.22%
194,650 $957,000
Q4 2023

Feb 06, 2024
SELL
$5.81 - $11.2 $116,780 - $225,120
-20,100 Reduced 10.88%
164,650 $1.45 Million
Q3 2023

Nov 08, 2023
BUY
$11.47 - $25.07 $25,234 - $55,154
2,200 Added 1.21%
184,750 $2.12 Million
Q2 2023

Aug 09, 2023
BUY
$24.7 - $37.61 $123,500 - $188,050
5,000 Added 2.82%
182,550 $4.62 Million
Q1 2023

May 10, 2023
SELL
$18.36 - $35.27 $335,988 - $645,441
-18,300 Reduced 9.34%
177,550 $5.72 Million
Q4 2022

Feb 08, 2023
BUY
$18.32 - $30.66 $78,776 - $131,838
4,300 Added 2.24%
195,850 $3.62 Million
Q3 2022

Nov 09, 2022
BUY
$14.33 - $28.47 $434,199 - $862,641
30,300 Added 18.79%
191,550 $5.17 Million
Q1 2022

May 09, 2022
BUY
$12.36 - $20.31 $145,848 - $239,657
11,800 Added 7.9%
161,250 $3.14 Million
Q2 2021

Aug 06, 2021
BUY
$26.8 - $31.84 $340,360 - $404,368
12,700 Added 9.29%
149,450 $4.43 Million
Q1 2021

May 07, 2021
BUY
$24.03 - $29.97 $62,478 - $77,922
2,600 Added 1.94%
136,750 $3.82 Million
Q4 2020

Feb 05, 2021
BUY
$23.41 - $28.34 $416,698 - $504,452
17,800 Added 15.3%
134,150 $3.8 Million
Q3 2020

Nov 09, 2020
BUY
$23.23 - $34.3 $44,137 - $65,169
1,900 Added 1.66%
116,350 $2.93 Million
Q2 2020

Aug 05, 2020
BUY
$12.6 - $26.55 $307,440 - $647,820
24,400 Added 27.1%
114,450 $2.8 Million
Q1 2020

May 08, 2020
BUY
$12.46 - $27.81 $13,706 - $30,591
1,100 Added 1.24%
90,050 $1.33 Million
Q4 2019

Feb 06, 2020
BUY
$11.66 - $20.15 $181,896 - $314,340
15,600 Added 21.27%
88,950 $1.44 Million
Q2 2019

Aug 02, 2019
BUY
$10.67 - $15.49 $41,613 - $60,411
3,900 Added 5.62%
73,350 $951,000
Q1 2019

May 10, 2019
BUY
$15.4 - $20.39 $264,880 - $350,708
17,200 Added 32.92%
69,450 $1.1 Million
Q4 2018

Feb 13, 2019
BUY
$18.06 - $24.96 $21,672 - $29,952
1,200 Added 2.35%
52,250 $1.05 Million
Q1 2018

May 04, 2018
SELL
$29.15 - $37.4 $17,490 - $22,440
-600 Reduced 1.16%
51,050 $1.57 Million
Q4 2017

Feb 07, 2018
BUY
$24.55 - $36.3 $397,710 - $588,060
16,200 Added 45.7%
51,650 $1.85 Million
Q3 2017

Nov 03, 2017
BUY
$22.55 - $28.1 $799,397 - $996,145
35,450
35,450 $977,000

Others Institutions Holding RVNC

# of Institutions
233
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Swiss National Bank Portfolio

Follow Swiss National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email